Long-term ethanol intake has been reported to evoke both hypertension and increase of systemic vasopressin levels in rats.
It has been well documented in clinical and experimental studies that hypertension is associated with long-term ethanol consumption. [1] [2] [3] However, the underlying mechanism of alcohol-induced hypertension is not fully understood.
Ethanol has been reported to influence peripheral vascular reactivity directly. 3, 4 Moreover, several mechanisms have been proposed to be involved with the hypertensive effect of long-term ethanol consumption, among them enhanced hormone secretion, increased neurotransmitter activity, sympathetic nervous system activation, and a myogenic mechanism that involves alteration in contractility of vascular smooth muscle. 1, 5 In addition, changes in baroreceptor activity could also contribute to the hypertensive state associated with long-term ethanol intake by rats. 3, 6 Ethanol consumption evokes diuresis and may cause dehydration, hypovolemia, and hyperosmolality, which are observed shortly after few days of forced ethanol consumption. 7 However, long-term ethanol consumption was associated with an antidiuretic effect in rats, 8 which results from increased systemic release of the antidiuretic hormone arginine vasopressin (AVP). 7 AVP is synthesized by the magnocellular neurons of the supraoptic (SON) and paraventricular (PVN) hypothalamic nuclei. Its release is increased during dehydration, promoting water conservation. AVP may also participate in the regulation of blood pressure through its vasoconstrictor effects. The acute treatment with the vasopressin antagonist dTyr(CH2)5(Me) AVP was reported to decrease arterial blood pressure in deoxycorticosterone acetate (DOCA) salt hypertensive rats, suggesting an AVP involvement in the blood pressure changes observed in that animal model. 9 Considering the above, it would be relevant to test the hypothesis that the hypertension associated with long-term ethanol consumption is caused by an increased AVP release into the systemic circulation.
To test this hypothesis, we submitted rats to 4 weeks of forced ethanol consumption; measured their blood pressure and the circulating AVP content; and studied the effect of the intravenous treatment with a V1-vasopressin antagonist on the mild hypertensive state associated with ethanol consumption. Rats initially weighing 300-350 g (80-100 days old) were randomly divided into two groups: control and ethanoltreated. Control rats drunk tap water ad libitum. Rats from the ethanol group received up to 20% (vol/vol) ethanol in their drinking water (adapted from refs. 3,10,11). All animals had free access to drinking. In order to avoid a considerable loss of animals, the ethanol-treated group was submitted to a brief and gradual adaptation period during which animals received 5% ethanol in their drinking water in the first week, 10% in the second, and 20% ethanol in the third and fourth weeks of experimentation.
METHODS

Long
Animal preparation. One day before the experiments, the rats were anesthetized with tribromoethanol (250 mg/kg) and a catheter (a 4-cm segment of PE-10 heat-bound to a 13-cm segment of PE-50, Clay Adams, Parsippany, NJ) was inserted into the abdominal aorta through the femoral artery, for blood pressure and heart rate (HR) recording. Whenever intravenous administration of drugs was necessary, a second catheter was implanted into the femoral vein. Both catheters were tunneled under the skin and exteriorized at the animal's dorsum.
Three groups of animals were used to perform the experiments. Each group was divided into ethanol and control animals. The first group was used to evaluate the effects of ethanol consume on basal values of arterial pressure and HR. Moreover, these animals were the same used to evaluate the effects of systemic administration of vasopressin antagonist, dTyr(CH2)5(Me)AVP, on the arterial pressure (ethanol: n = 7 and control: n = 5). The second group was used to evaluate the plasma vasopressin concentration in ethanol and control animal (ethanol: n = 7 and control: n = 5). Finally, the third group of animals was used to evaluate the vasopressin-mRNA expression in two hypothalamic nuclei (ethanol: n = 16 and control: n = 15). In the two last experiments (determination of plasma vasopressin, concentration, and vasopressin-mRNA expression), the animals had the cardiovascular basal levels measured to confirm the results of ethanol consume on arterial blood pressure.
Measurement of cardiovascular responses. During the experiment, the freely moving rats were kept in individual cages and the mean arterial pressure (MAP), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and HR were recorded using a HP-7754A amplifier (Hewlett Packard, Palo Alto, CA) connected to a signal acquisition board (MP-100, BIOPAC, Goleta, CA) and were computer processed.
Plasma AVP radioimmunoassay. Two-milliliter blood samples were collected from each animal from both groups. AVP was extracted from 1 ml plasma samples using acetone and petroleum ether. 12 AVP recovery was 82%. AVP antiserum was purchased from Peninsula Laboratories (Belmont, CA) and [125]I-AVP from Laboratory of Neuroendocrinology, Department of Physiology. The assay sensitivity was 0.58 pmol/l. Intra-and interassay coefficients of variation were 2.7 and 17%, respectively. Duplicate samples from each subject were processed in the same assay.
Sample collection and RNA extraction. Animals were decapitated between 9.00 and 10.00 am. After decapitation, the brains were collected in RNAse-free conditions and were immediately frozen in dry ice for storage at −80 °C before hypothalamic vasopressin-mRNA determination.
Using a stainless steel punch needle of 1.5 mm diameter, microdissections were obtained in a cryostat according to the coordinates from Paxinos and Watson atlas (1997): PVN and SON: 1,200 µm; −0.92 to −2.12 from bregma. Tissue samples were transferred into a microtube with RNAlater reagent (Ambion, Austin, TX) and stored at 4 °C for a maximum of 24 h before RNA isolation.
Total RNA was isolated from each micropunched hypothalamic tissue sample using TRIzol reagent (Invitrogen, Auckland, New Zealand), according to the directions supplied by the manufacturer. Briefly, TRIzol (750 µl/micrutube) was added to the sample, shaken for 30 s, and incubated at dry ice for 5 min. To each 1 ml of the suspension, 200 µl of chloroform (Sigma, St Louis, MO) and 10 µl of glycogen (20 mg/ml) were added, vortexed, incubated at room temperature for 5 min and then centrifuged at 14,000 r.p.m. by 25 min at 4 °C. The aqueous phase was transferred into a new microtube, to which 500 µl of isopropanol (Sigma, St Louis, MO) was added. The sample was vortexed and incubated overnight at −80 °C. On the next day, the samples were centrifuged at 14,000 r.p.m. for 15 min at 4 °C. The pellet was washed with 70% ethanol, centrifuged at 14,000 r.p.m. for 15 min at 4 °C, and dried at room temperature. RNA samples were resuspended in 15 µl of diethylpyrocarbonate-treated water and stored at −80 °C. The concentration of RNA was determined using UV spectrophotometer and then 250 ng of RNA was used for complementary DNA synthesis, using high capacity complementary DNA reverse transcription kit (Applied Biosystems, Foster City, CA).
Real-time-PCRs. Quantitative real-time PCR was performed using an Applied Biosystems 7500 Real-Time PCR System. The following TaqMan Gene Expression Assays (Applied Biosystems) were used in this study: Rn 00566449 (AVP). The PCR was performed in triplicates. Water instead of complementary DNA was used as a negative control. Housekeeping genes (β-actin and GAPDH) were run for each complementary DNA sample. Determination of gene transcript in each sample made by the ΔΔCT method. For each sample, the threshold cycle (C t ) of mRNA was measured and normalized to the average of the housekeeping genes (ΔC t = C t Unknown -C t Housekeeping genes). The fold change of mRNA in the unknown sample relative to the control group was determined by 2−ΔΔC t , where Drugs. The following drugs were used: ethanol (Labsynth, Vila Nogueira, Brazil), tribromoethanol (Aldrich, Washington, DC), and dTyr(CH2)5(Me)AVP (Peninsula, Belmont, CA).
Statistical analysis. The MAP and HR baseline of each group was compared using Student's t-test. Two-way analysis of variance (treatment vs. condition) followed by the Bonferroni's post hoc test was used to compare MAP and HR changes caused by systemically administered (treatment) AVP antagonist (dTyr(CH2)5(Me)AVP) or vehicle in long-term ethanoltreated or control animals (condition).
The AVP plasma levels and possible differences in the intensity of AVP-mRNA expression of ethanol-treated and control rats were compared using the Student's t-test. Results of statistical tests with P < 0.05 were considered significant.
RESULTS
The group that consumed ethanol had lower gain of weight when compared with the control group, during the time of treatment (456 ± 18 vs. 535 ± 11 g, respectively; two-way analysis of variance, F = 20.5, P < 0.01, n = 5-7). No changes in ethanol or water consumption were observed after implantation of femoral catheters (two-way analysis of variance, F = 2.5, P > 0.5, n = 5-7). Table 1) . No HR differences were observed among the groups ( Table 1) .
Plasma AVP content was found to be 30% higher in ethanol-treated animals (3 ± 0.1 pg/ml, n = 7) in comparison to control animals (2.3 ± 0.05 pg/ml, n = 5, t = 6.4, P < 0.001, Figure 2) . Moreover, AVP-mRNA expression was found to be increased in both the SON (n = 7) and the PVN (n = 9) of ethanol-treated animals when compared to control animals (SON: t = 3.9, P < 0.05, n = 8 and PVN: t = 2, P < 0.05, n = 7, Figure 2) .
Effect of systemic treatment with dTyr(CH2)5(Me)AVP on the arterial pressure of rats submitted to long-term ethanol consumption Two-way analysis of variance showed significant effects of treatment (MAP: F = 44, P < 0.001; SAP: F = 15, P < 0.01; DAP: F = 20, P < 0.001) and condition (MAP: F = 79, P < 0.001; SAP: F = 9, P < 0.01; DAP: F = 28, P < 0.001) on arterial pressure. In addition, there was a significant interaction between treatment and condition factors (MAP: F = 54, P < 0.001; SAP: F = 20, P < 0.01; DAP: F = 40, P < 0.001). No changes were observed in HR (P > 0.05).
The IV pretreatment with dTyr(CH2)5(Me)AVP (50 mg/kg, IV) did not affect MAP (before: 91 ± 3 mm Hg and after: 96 ± 2 mm Hg, F = 3, P > 0.05), SAP (before: 120 ± 3 mm Hg and after: 124 ± 3 mm Hg, F = 1.7, P > 0.05), DAP (before: 83 ± 3 mm Hg and after: 84 ± 2 mm Hg, F = 0.1, P > 0.05) or HR (before: 345 ± 11 bpm and after: 368 ± 10 bpm, F = 1.3, P > 0.05) of control animals (n = 5, Figure 3 ). 
Table 1 | Basal values of HR, MAP, SAP, and DAP obtained from control and ethanol-treated rats
Group HR (bpm) MAP (mm Hg) SAP (mm Hg) DAP (mm Hg)
Control (n = 5) 344 ±11 92 ± 3 119 ± 3 79 ± 3
Ethanol (n = 7) 353 ± 9 121 ± 3 145 ± 4 102 ± 2 P > 0.05 P < 0.01 P < 0.01
Values are means ± s.e.m., Student's t-test. DAP, diastolic arterial pressure; HR, heart rate; MAP, mean arterial pressure; SAP, systolic arterial pressure. 
Vasopressin and Ethanol-induced Hypertension
However, in ethanol-treated animals (n = 7), dTyr(CH2)5 (Me)AVP caused a significant reduction in MAP (before: 123 ± 3 mm Hg and after: 88 ± 3 mm Hg, F = 51, P < 0.001), SAP (before: 145 ± 5 mm Hg and after: 107 ± 4 mm Hg, F = 29, P < 0.001), and DAP (before: 103 ± 2 mm Hg and after: 70 ± 4 mm Hg, F = 52, P < 0.001, Figure 3) . No cardiovascular changes were observed after IV administration of the vehicle (control: P > 0.05 and ethanol: P > 0.05, Figure 3 ) in either group of animals. Vehicle administration had no effect on baseline blood pressure or HR in either group of animals (Figure 3) . Figure 4 shows representative recordings of MAP and HR of ethanol-treated and control rats before and after IV administration of dTyr(CH2)5(Me)AVP.
DISCUSSION
Long-term ethanol (20% vol/vol) intake for 2 weeks evoked an MAP increase in rats. The blood pressure increase was the result of a rise in both systolic and DAPs. This observation is in agreement with previous results from our laboratory. 3 Because blood pressure was increased after just a 2-week period of forced consumption of 20% ethanol, our results support the idea that the hypertensive state associated with ethanol intake can already be observed at early stages of high ethanol consumption. As previously stated, the rise in blood pressure evoked by long-term ethanol consumption can be attributed to several mechanisms, including secretion of hormones and neurotransmitters, stimulation of the sympathetic nervous system, alteration of baroreceptor activity, and volume overload.
Ethanol ingestion affects the hypothalamo-neurohypophysial system resulting in increased diuresis, dehydration, and hyperosmolality. 13 The negative water balance during initial exposure to ethanol evokes AVP release, which promotes water reabsortion by the kidney and is a potent vasoconstrictor agent. 14 AVP is synthesized by magnocellular neurons of the SON and PVN being released into the systemic circulation by the posterior hypophysis, following appropriate stimuli (e.g., osmotic challenges and dehydration). 15 Considering that AVP is released in response to blood volume decrease and diuresis and also that long-term ethanol consumption has a negative effect on water volume in rats, 8 the concentration of vasopressin in the systemic circulation should be increased during long-term ethanol ingestion.
The measurement of AVP blood content showed an increase of 30% in circulating AVP in rats treated chronically with ethanol in comparison to the levels measured in the blood of control animals. Moreover, it was observed that the expression , and heart rate (HR) of long-term ethanol-treated (n = 7) and control animals (n = 5). the bars represent the mean ± s.e.m. *P < 0.05, compared with control values before administration, # compared with ethanol values before administration using a two-way ANOVA followed by Bonferroni's post hoc test. These results are in agreement with previous results showing that ethanol consumption could lead to an increase in circulating AVP. 16 Moreover, it has been proposed that dehydration is a reason to assume that the SON neurons of long-term ethanol-treated rats are engaged in the production of large amounts of hormones, including AVP. 17 The enhanced activity of these neurons might result from a direct action of ethanol upon them 17 or alternatively from dehydration and hyperosmolality, which are known as side effects of long-term ethanol consumption by experimental animals. 18 Because ethanol consumption may lead to an increased blood AVP content, and considering that AVP is a potent vasoconstrictor agent 14 and can increase the arterial pressure of rats when released systemically, [19] [20] [21] it is possible that AVP could be involved in the maintenance of the hypertension associated with longterm ethanol consumption.
To test this hypothesis, we studied the effect of IV treatment with a V1-vasopressin receptor antagonist, dTyr(CH2)5(Me) AVP, on the blood pressure of ethanol-treated and control animals. Treatment with the vasopressin antagonist reduced the baseline blood pressure of ethanol-treated animals to the values observed in control animals, whereas no changes were observed in that of control animals, suggesting that the hypertensive state observed under long-term ethanol treatment is mediated by AVP, which is released into the circulation in response to long-term ethanol ingestion.
Under other conditions of hypertension, the vascular effects of AVP also may contribute to the maintenance of high blood pressure. For example, AVP seems to participate in the pathogenesis of DOCA-salt hypertension through both its vasoconstrictor and its antidiuretic effects. 9 In conscious rats having established DOCA-salt hypertension, d(CH2)5 Tyr (Me) AVP decreased systolic BP after its acute injection. After longterm treatment with this antagonist for 6 weeks, the severity of DOCA-salt treatment-induced hypertension was reduced. 9 These results are in agreement with our ethanol results, showing that AVP could be involved in hypertensive responses.
Although long-term ethanol consumption has usually been associated with hypertension, there are results showing that long-term ethanol consumption lowered or did not affect arterial blood pressure in rats. 22 These results indicate that two factors might account for the lack of hypertension in ethanoltreated animals, which are the ethanol exposure period and the use of anesthesia. Anesthetic agents could depress cardiovascular function more severely in ethanol-treated rats than in control rats, yielding similar blood pressure values. Actually, there are reports of a positive correlation between the extent of ethanol intake and the development of hypertension, 3, 23, 24 suggesting that the period of exposure to ethanol is a major factor in the development of hypertension. However, the duration of long-term ethanol consumption and the volume of ethanol in the diet differ among the several studies published, 3, 5, 6, 23, 25 which makes it difficult to draw a final conclusion.
It is important to consider that baroreflex is altered in ethanol-treated animals. The baroreflex gain was reduced after a 2-week ethanol treatment in rats, indicating an impairment of baroreflex function after ethanol consumption. 3 Previously, Abdel-Rahman et al. 6 demonstrated that the baroreflex activity of rats chronically treated with ethanol was reduced before any rise in blood pressure had occurred. The alterations in arterial baroreflex evoked by long-term ethanol consumption were secondary to MAP changes because MAP was higher in 2-week ethanol-treated rats. 3 However, it is tempting to suggest that impairment of arterial baroreflex may be an important factor only for the development of ethanol-induced hypertension but not to maintain the hypertensive state.
It has been described that the pressor response is increased when baroreflex sensitivity is depressed 26 and that there is a negative correlation between the pressor response to phenylephrine and averaged baroreflex interbeat interval sensitivity. 27 We previously reported that the pressor response to phenylephrine IV infusion was enhanced in 2-week ethanoltreated rats. 3 This increased responsiveness to phenylephrine could be related to an enhanced baroreflex activity. Thus, the depression in the sympathetic system induced by the enhanced baroreflex activity could lead to a hypersensitivity to the exogenous α-adrenoreceptor agonist. Strickland and Wooles 24 reported that the response to phenylephrine of isolated rat thoracic aortas from rats that are chronically fed ethanol was depressed and that the blood pressure of the ethanol-treated group was significantly higher than that of the control group. These results suggest that sympathetic system activity is reduced after 2 weeks of ethanol treatment as a reflex response evoked by MAP increases caused by rises of AVP blood levels.
In summary, our findings indicate that a significant MAP increase is already observed at an early phase of long-term ethanol consumption, being associated with an increase in AVP plasma content. The idea of an involvement of circulating AVP in the mediation of the mild hypertensive state observed in ethanol-treated rats is favored because treatment with a selective V1-vasopressinergic receptor antagonist blocked the ethanol-induced hypertension in rats. However, more studies should be conducted to extend these observations to human hypertension associated with alcohol consumption.
